Abstract
On the occasion of its recent approval for relapsed follicular lymphoma, we review the design and development of the pan-class I PI3K inhibitor copanlisib as a drug for the treatment of B-cell malignancies in comparison with other kinase inhibitors targeting B-cell-receptor signaling, in particular with strictly isoform-δ-selective idelalisib. In agreement with previously defined PI3K-inhibitor chemotypes, the 2,3-dihydroimidazo[1,2-c]quinazoline scaffold of copanlisib adopts a flat conformation in the adenine-binding pocket of the catalytic p110 subunit and further extends into a deeper-affinity pocket in contrast to idelalisib, the quinazoline moiety of which is accommodated in a newly created selectivity pocket. Copanlisib shows higher potency than other clinically developed PI3K inhibitors against all four class I isoforms, with approximately tenfold preference for p110α and p110δ. Owing to its potency and isoform profile, copanlisib exhibits cell-type-specific cytotoxicity against primary chronic lymphocytic leukemia cells and diffuse large B-cell lymphoma (DLBCL) cell lines at nanomolar concentrations. Moreover, copanlisib differs from idelalisib in regard to intravenous versus oral administration and weekly versus twice-...Continue Reading
Citations
Mar 1, 2019·Biomolecules·Michelle S MillerSandra B Gabelli
Oct 12, 2019·BMC Cancer·Joo Hyun KimChaehwa Park
Jan 19, 2020·Cells·Adrián MontañoJesús María Hernández-Rivas
Jul 28, 2019·The Oncologist·Matthew J MatasarJessica Okosun
Mar 4, 2020·Blood Advances·Chiara TarantelliFrancesco Bertoni
Jun 25, 2020·Expert Review of Clinical Pharmacology·Massimo MagagnoliArmando Santoro
Sep 3, 2020·Blood Advances·Arne KolstadHarald Holte
Sep 8, 2020·Drugs·Sara E Nunnery, Ingrid A Mayer
Sep 20, 2020·Rheumatology·Maria JuarezSimon J Bowman
Jun 20, 2019·Frontiers in Oncology·Stefania CrisciAntonio Pinto
Jan 24, 2019·International Journal of Molecular Sciences·Vanessa Edna SanchezYong-Mi Kim
Dec 9, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Folayemi AdefemiAaron J Marshall
Dec 14, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elizabeth A LemmGraham Packham
May 7, 2020·Molecular Cancer Therapeutics·Alfonso García-ValverdeCésar Serrano
Nov 3, 2020·Clinical Lymphoma, Myeloma & Leukemia·Tycel J PhillipsVincent Ribrag
Nov 4, 2020·Cell Death & Disease·Ji YanHongmei Zhao
Feb 4, 2021·Cancer Management and Research·Ayushi F Chauhan, Bruce D Cheson
Nov 7, 2020·Frontiers in Oncology·Laura Ondrisova, Marek Mraz
Apr 4, 2021·Cancers·Valerio Guarente, Paolo Sportoletti
Apr 24, 2021·Therapeutic Advances in Hematology·Thuy LeLocke J Bryan
Jul 1, 2021·BMC Cancer·Alexander GrunenbergChristian Buske
Aug 7, 2021·Genes·Cristina CuestaEsther Castellano
Aug 7, 2021·Leukemia & Lymphoma·Sarah M RidgeDorothy A Sipkins
Dec 2, 2021·CPT: Pharmacometrics & Systems Pharmacology·Kapil GadkarSaroja Ramanujan